publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
predictor
incid
allcaus
mortal
death
due
diabet
renal
diseas
among
patient
newli
prescrib
antihypertens
agent
cohort
studi
background
random
trial
shown
major
antihypertens
drug
class
similarli
effect
reduc
mortal
whether
drug
class
differ
exist
clinic
practic
scarc
explor
studi
evalu
associ
antihypertens
drug
class
allcaus
mortal
death
due
diabet
renal
diseas
reallif
clinic
set
method
clinic
databas
hong
kong
includ
patient
prescrib
firstev
antihypertens
agent
public
healthcar
sector
patient
follow
five
year
group
accord
initi
antihypertens
prescript
associ
antihypertens
drug
class
allcaus
mortal
combin
diabet
renal
mortal
respect
evalu
cox
proport
hazard
model
result
elig
patient
die
within
five
year
firstev
antihypertens
prescript
among
patient
die
diabet
renal
diseas
adjust
age
gender
socioeconom
statu
servic
set
district
resid
medic
adher
number
comorbid
drug
class
similarli
like
associ
mortal
due
diabet
renal
diseas
adjust
hazard
ratio
ahr
rang
p
allcaus
mortal
ahr
rang
except
betablock
ahr
ci
p
acei
use
refer
group
propens
scoreadjust
analysi
conclus
find
provid
reallif
evid
reinforc
major
antihypertens
drug
class
suitabl
firstlin
agent
manag
hypertens
recommend
intern
guidelin
variou
intern
guidelin
recommend
choic
firstlin
antihypertens
agent
manag
arteri
hypertens
base
high
qualiti
random
control
trial
rct
joint
nation
committe
jnc
seventh
report
reapprais
hypertens
european
guidelin
propos
thiazid
diuret
calcium
channel
blocker
ccb
angiotensin
convert
enzym
inhibitor
aeci
angiotensin
receptor
blocker
arb
prefer
firstlin
option
base
observ
landmark
rct
major
class
antihypertens
drug
except
shown
reduc
morbid
mortalityand
exist
differ
among
howev
guidelin
issu
nation
institut
health
clinic
excel
nice
assist
british
hypertens
societi
drop
firstlin
agent
owe
suboptim
outcom
recent
clinic
trial
kaplan
victor
state
choic
antihypertens
therapi
particularli
firstlin
agent
made
care
patient
less
sever
hypertens
treat
medic
task
forc
manag
arteri
hypertens
european
societi
hypertens
esh
european
societi
cardiolog
esc
long
recogn
limit
eventbas
random
therapeut
trial
includ
need
select
elderli
higher
risk
patient
maxim
number
event
collect
achiev
adequ
studi
power
result
younger
uncompl
patient
lower
cardiovascular
risk
underrepres
littl
inform
avail
treatment
benefit
larg
number
hypertens
popul
anoth
import
caveat
therapeut
program
rct
usual
diverg
usual
clinic
practic
sinc
drug
randomli
alloc
trial
commenc
continu
irrespect
blood
pressur
lower
effect
clinic
practic
physician
normal
continu
prescript
ineffect
trial
benefit
confer
patient
therefor
dilut
lack
benefit
nonrespons
patient
usual
short
durationwhich
impli
generaliz
gener
popul
limit
random
trial
interpret
parallel
observ
studi
achiev
balanc
decis
regard
choic
prefer
firstlin
antihypertens
agent
jnc
eighth
report
current
prepar
committe
decid
whether
remain
firstlin
agent
releg
fourthlin
agent
task
requir
incorpor
observ
studi
addit
newer
random
outcom
trial
nevertheless
scarciti
larg
scale
observ
studi
could
inform
guidelin
recommend
previous
studi
complianc
profil
year
incid
cardiovascular
mortal
larg
chines
popul
newli
prescrib
antihypertens
medic
attempt
provid
reallif
clinic
data
present
unknown
whether
major
antihypertens
drug
class
superior
term
prevent
death
due
caus
diabet
renal
diseas
nonintervent
set
object
studi
test
priori
hypothesi
incid
allcaus
mortal
death
due
diabet
kidney
diseas
respect
similar
among
major
antihypertens
drug
class
firstlin
agent
secondari
object
studi
identifi
patient
higher
risk
allcaus
diabetesand
renal
diseaserel
mortal
five
year
antihypertens
prescript
computer
databas
known
electron
clinic
manag
system
hong
kong
previous
describ
detail
briefli
databas
captur
patient
demograph
paramet
prescript
detail
clinic
diagnos
form
intern
classif
diseas
intern
classif
primari
care
serv
sole
portal
data
entri
allow
linkag
physicianent
inform
patient
visit
public
clinic
set
among
differ
district
drug
prescript
input
attend
physician
crosscheck
dispens
pharmacist
use
standard
procedur
amend
prescript
initi
consult
also
record
system
databas
previous
valid
demonstr
high
level
complet
sociodemograph
inform
prescript
profil
sampl
frame
present
studi
includ
entir
hong
kong
popul
hong
kong
divid
three
distinct
region
name
hong
kong
island
urban
kowloon
new
territori
rural
ethic
clearanc
studi
obtain
clinic
ethic
research
committe
hospit
author
survey
behavior
research
ethic
committe
chines
univers
hong
kong
inform
consent
necessari
subject
anonym
uniqu
ident
number
studi
protocol
conform
ethic
guidelin
declar
helsinki
databas
patient
consult
public
practic
prescrib
firstev
antihypertens
agent
calendar
year
index
date
includ
detail
calendar
year
exclud
due
substanti
disrupt
clinic
servic
result
outbreak
sever
acut
respiratori
syndrom
patient
receiv
antihypertens
medic
index
date
exclud
captur
patient
die
diabet
renal
diseas
treat
death
due
condit
two
diseas
within
observ
period
censor
patient
alloc
base
initi
prescript
antihypertens
agent
name
thiazid
diuret
ccb
acei
patient
prescrib
arb
combin
therapi
exclud
data
analysi
prescript
rel
rare
concomit
comorbid
includ
cardiovascular
risk
factor
medic
condit
could
potenti
confound
choic
antihypertens
drug
class
indic
respect
code
patient
follow
occurr
mortal
within
studi
period
end
five
year
outcom
variabl
allcaus
mortal
death
due
diabet
mellitu
renal
diseas
respect
vast
major
death
hong
kong
occur
hospit
allow
accur
case
ascertain
number
previou
studi
util
death
hospit
valid
proxi
patient
mortal
especi
chines
popul
death
usual
occur
hospit
caus
death
due
diabet
eg
diabet
ketoacidosi
hyperosmolar
nonketot
diabet
coma
renal
diseas
eg
uremia
defin
accord
primari
caus
mortal
patient
determin
physiciansincharg
death
regist
death
certif
predictor
variabl
studi
major
class
antihypertens
drug
initi
prescript
intervalbas
proport
day
cover
pdc
includ
covari
take
consider
influenc
medic
adher
potenti
confound
pdc
refer
number
day
medic
suppli
specifi
period
divid
total
number
day
within
period
intervalbas
measur
pdc
intern
accept
metric
assess
drug
adher
larg
databas
analysi
studi
fiveyear
interv
use
estim
pdc
patient
die
fiveyear
period
time
period
index
date
mortal
use
estim
pdc
similar
approach
adopt
mazzaglia
colleagu
drug
adher
present
studi
divid
two
level
name
high
intermedi
pdc
low
pdc
b
addit
also
evalu
rate
medic
discontinu
switch
among
patient
drug
switch
defin
absenc
refil
prescript
subsequ
clinic
visit
combin
prescript
anoth
antihypertens
drug
differ
class
sinc
date
first
prescript
wherea
drug
discontinu
refer
repeat
prescript
drug
class
last
day
specifi
period
firstev
antihypertens
prescript
date
accord
intern
literatur
use
year
year
year
year
year
respect
time
point
measur
two
outcom
independ
variabl
control
includ
patient
age
gender
payment
statu
recipi
vs
nonrecipi
comprehens
social
secur
assist
consult
primari
care
set
cost
approxim
us
includ
investig
prescript
fee
clinic
type
inand
daypati
clinic
specialist
outpati
clinic
sopc
accid
emerg
depart
a
gener
outpati
clinic
gopc
clinic
type
district
resid
hong
kong
island
vs
kowloon
vs
new
territori
urban
rural
respect
number
concomit
comorbid
read
systol
diastol
blood
pressur
averag
clinic
visit
list
comorbid
code
use
present
studi
publish
elsewher
categor
diabet
impair
glucos
toler
cardiovascular
diseas
respiratori
diseas
renal
diseas
descript
analysi
student
test
chisquar
test
heterogen
use
compar
continu
categor
variabl
respect
variabl
list
enter
one
coxproport
hazard
model
explor
associ
initi
antihypertens
drug
class
mortal
caus
mortal
combin
death
due
diabet
renal
diseas
respect
outcom
variabl
account
confound
effect
medic
chang
studi
particip
censor
switch
studi
medic
discontinu
treatment
case
follow
day
last
prescript
identifi
event
may
precipit
discontinu
commenc
treatment
differ
antihypertens
agent
reach
end
studi
accord
methodolog
adopt
dhalla
et
al
follow
patient
maximum
year
also
conduct
sensit
analysi
patient
whose
antihypertens
drug
class
switch
ad
anoth
drug
class
exclud
similar
regress
model
construct
detect
chang
associ
factor
identifi
addit
propens
score
model
develop
estim
weight
adher
select
name
high
intermedi
vs
low
adher
given
possibl
exist
treatment
indic
bia
due
observ
natur
studi
therefor
analysi
perform
adjust
estim
weight
invers
estim
propens
score
two
cox
proport
hazard
model
accord
standard
statist
methodolog
minim
influenc
indic
bia
due
differ
baselin
characterist
patient
highdimension
propens
score
match
compar
patient
similar
observ
characterist
adopt
use
standard
methodolog
util
literatur
recipi
one
antihypertens
drug
class
match
recipi
anoth
antihypertens
class
basi
age
index
date
within
year
sex
calendar
year
treatment
initi
propens
score
within
sd
evalu
multicollinear
interact
among
variabl
ensur
robust
regress
model
statist
packag
social
scienc
version
spss
inc
use
data
analys
p
valu
b
regard
statist
signific
total
elig
patient
includ
tabl
femal
patient
age
year
older
receiv
public
assist
major
follow
inor
daypati
clinic
special
outpati
clinic
patient
live
rural
region
new
territori
kowloon
respect
commonli
prescrib
antihypertens
agent
betablock
ccb
follow
acei
thiazid
diuret
patient
prescrib
alphablock
firstlin
agent
patient
intermedi
good
adher
major
one
comorbid
less
tabl
show
cumul
incid
medic
discontinu
switch
shortand
longterm
user
alphablock
betablock
highest
discontinu
rate
wherea
thiazid
diuret
acei
highest
switch
rate
total
patient
die
within
five
year
firstev
antihypertens
prescript
tabl
among
die
due
diabet
renal
diseas
univari
analysi
elderli
patient
p
b
male
subject
p
receiv
social
secur
allow
p
b
like
experi
allcaus
mortal
death
due
diabet
renal
diseas
addit
patient
attend
inpati
daypati
clinic
special
outpati
clinic
like
suffer
mortal
p
b
district
resid
adher
level
antihypertens
agent
also
signific
factor
proport
patient
die
increas
number
comorbid
steep
doserespons
manner
proport
allcaus
mortal
highest
among
user
ccb
acei
alphablock
follow
thiazid
diuret
betablock
regard
death
due
diabet
renal
diseas
tabl
patient
prescrib
ccb
acei
highest
rate
mortal
follow
thiazid
diuret
alphablock
betablock
p
b
cox
proport
hazard
analysi
allcaus
mortal
outcom
measur
tabl
found
advanc
age
class
antihypertens
agent
prescrib
significantli
associ
incid
mortal
ahr
rang
p
except
betablock
ahr
ci
p
howev
group
betablock
confin
centrallyact
agent
rel
hazard
becam
insignific
ahr
ci
p
death
due
diabet
renal
diseas
associ
factor
similar
except
gender
receipt
public
assist
medic
adher
report
statist
signific
compar
acei
variou
drug
class
similarli
associ
combin
diabet
renal
mortal
ahr
rang
p
highdimension
propens
score
match
use
compar
patient
similar
characterist
factor
associ
outcom
drug
class
comparison
remain
unchang
addit
sensit
analysi
exclus
patient
whose
medic
switch
ad
anoth
drug
class
detect
differ
associ
factor
identifi
exist
interact
multicollinear
among
predictor
variabl
impli
regress
analysi
robust
present
find
show
gener
major
class
antihypertens
agent
similarli
like
associ
allcaus
mortal
death
due
diabet
renal
diseas
use
firstlin
agent
among
antihypertensivena
patient
patient
receiv
betablock
seem
suffer
lower
incid
allcaus
mortal
case
centrallyact
agent
addit
factor
associ
mortal
identifi
includ
old
age
presenc
comorbid
healthcar
set
secondari
care
result
base
observ
nonintervent
set
bear
signific
implic
clinician
choic
firstlin
antihypertens
prescript
recent
metaanalysi
rct
compar
incid
allcaus
mortal
among
major
antihypertens
drug
class
show
differ
patient
initi
prescrib
betablock
diuret
reninangiotensin
system
inhibitor
allcaus
mortal
rate
margin
higher
betablock
compar
ccb
rel
risk
ci
howev
author
recogn
grade
evid
find
low
achiev
midlevel
evid
indic
true
effect
betablock
may
substanti
differ
review
estim
anoth
metaanalysi
involv
studi
correspond
group
comparison
weight
mean
followup
year
demonstr
exist
slightli
smaller
risk
endstag
renal
failur
among
acei
arb
user
antihypertens
user
rel
risk
ci
p
acei
arb
group
also
associ
statist
signific
smaller
serum
creatinin
chang
ci
also
urin
albumin
excret
mgday
ci
howev
benefit
attribut
lower
blood
pressur
per
se
rather
antihypertens
drug
class
use
posthoc
analysi
antihypertens
lipidlow
treatment
prevent
heart
attack
trial
allhat
among
hypertens
patient
age
year
older
least
one
cardiovascular
risk
factor
signific
differ
found
incid
endstag
renal
failur
decrement
glomerular
filtrat
rate
furthermor
one
signific
factor
could
potenti
favor
effect
reduc
mortal
name
nation
salt
intak
level
dietari
salt
intak
hong
kong
high
time
studi
particip
recruit
averag
sodium
intak
hong
kong
popul
mmolday
gday
higher
western
countri
also
level
recommend
b
gday
find
therefor
interpret
light
potenti
confound
turn
incid
diabetesfrom
allhat
trial
patient
without
diabet
baselin
higher
incid
diabet
year
thiazid
diuret
group
ccb
acei
group
nevertheless
metabol
differ
translat
overal
disadvantag
thiazid
diuret
group
averag
followup
year
furthermor
addit
epidemiolog
analysi
examin
associ
year
fast
glucos
chang
cardiovascular
diseas
renal
event
report
signific
overal
separ
diuret
group
also
among
develop
incid
diabet
year
compar
subsequ
increas
risk
major
diseas
outcom
mortal
except
congest
heart
failur
thu
far
awar
largescal
observ
studi
compar
major
antihypertens
drug
class
mortal
rate
tabl
cumul
incid
antihypertens
drug
discontinu
switch
differ
time
point
acei
angiotensin
convert
enzym
inhibitor
ccb
calcium
channel
blocker
drug
switch
defin
absenc
refil
prescript
subsequ
clinic
visit
combin
prescript
anoth
antihypertens
drug
differ
class
sinc
date
first
prescript
drug
discontinu
refer
repeat
prescript
drug
class
last
day
specifi
period
firstev
antihypertens
prescript
date
tabl
number
percentag
allcaus
mortal
death
due
diabet
renal
diseas
within
year
initi
antihypertens
prescript
first
largest
observ
studi
evalu
factor
associ
allcaus
noncardiovascular
mortal
larg
chines
popul
complet
databas
good
dispens
practic
make
studi
find
robust
addit
accuraci
independ
variabl
antihypertens
drug
class
outcom
measur
mortal
strengthen
result
howev
limit
address
firstli
assum
patient
take
medic
prescrib
document
databas
inher
assumpt
databas
studi
furthermor
dataset
consist
potenti
confound
could
control
sever
comorbid
blood
pressur
level
covari
includ
lifestyl
factor
routin
captur
clinic
databas
moreov
indic
bia
treatment
accord
medic
class
exist
despit
use
propens
score
one
might
also
argu
regress
analysi
could
complet
control
confound
presenc
residu
confound
lastli
critic
might
comment
durat
observ
mortal
year
initi
antihypertens
prescript
might
long
enough
captur
clinic
meaning
outcom
prolong
observ
period
warrant
futur
studi
present
find
show
major
drug
class
similar
term
allcaus
well
combin
diabet
renal
mortal
respect
observ
data
strengthen
find
rct
conduct
intervent
set
find
therefor
compat
intern
guidelin
physician
deter
prescrib
betablock
firstlin
antihypertens
drug
manag
arteri
hypertens
studi
ad
evid
exist
find
eventbas
random
therapeut
trial
major
antihypertens
drug
class
suitabl
firstlin
agent
manag
hypertens
